Company Overview

GT Biopharma, Inc. (OTCQB: GTBP) (GTBP.PA) is a clinical stage immuno-oncology company focused on innovative therapies based on the Company's proprietary NK cell engager (TriKE™) technology. TriKE™ therapeutic agents are targeted immunotherapeutic agents that have been modified from a bispecific antibody platform. TriKE agents are immune cell engagers that simultaneously react with natural killer (NK) cells and cancer cells to selectively facilitate the killing of cancer cells by NK cells.